TY - JOUR
T1 - ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity
AU - Ron, Idit
AU - Horowitz, Mia
N1 - Funding Information:
We are indebted to Professor Shoshana Bar-Nun from the Department of Biochemistry at Tel Aviv University for excellent advices, very fruitful discussions and critical reading of the manuscript. We would like to thank Dr R. Gravel for anti-β-hexosaminidase A antibodies, to A. Barbul for assistance with confocal microscopy and to Professor A. Zimran and Dr D. Elstein from the Gaucher Clinic, Shaare-Zedek Medical Center, Jerusalem for critical reading of the manuscript. This work was supported by a grant from the Israel Science Foundation (Grant no. 648/02).
PY - 2005/8/15
Y1 - 2005/8/15
N2 - Gaucher disease (GD), an autosomal recessive disease, is characterized by accumulation of glucosylceramide mainly in cells of the reticuloendothelial system, due to mutations in the acid β-glucocerebrosidase gene. Some of the patients suffer from neurological symptoms (type 2 and type 3 patients), whereas patients with type 1 GD do not present neurological signs. The disease is heterogeneous even among patients with the same genotype, implicating that a mutation in the glucocerebrosidase gene is required to cause GD but other factors play an important role in the manifestation of the disease. Glucocerebrosidase is a lysosomal enzyme, synthesized on endoplasmic reticulum (ER)-bound polyribosomes and translocated into the ER. Following N-linked glycosylations, it is transported to the Golgi apparatus, from where it is trafficked to the lysosomes. In this study, we tested glucocerebrosidase protein levels, N-glycans processing and intracellular localization in skin fibroblasts derived from patients with GD. Our results strongly suggest that mutant glucocerebrosidase variants present variable levels of ER retention and undergo ER-associated degradation in the proteasomes. The degree of ER retention and proteasomal degradation is one of the factors that determine GD severity.
AB - Gaucher disease (GD), an autosomal recessive disease, is characterized by accumulation of glucosylceramide mainly in cells of the reticuloendothelial system, due to mutations in the acid β-glucocerebrosidase gene. Some of the patients suffer from neurological symptoms (type 2 and type 3 patients), whereas patients with type 1 GD do not present neurological signs. The disease is heterogeneous even among patients with the same genotype, implicating that a mutation in the glucocerebrosidase gene is required to cause GD but other factors play an important role in the manifestation of the disease. Glucocerebrosidase is a lysosomal enzyme, synthesized on endoplasmic reticulum (ER)-bound polyribosomes and translocated into the ER. Following N-linked glycosylations, it is transported to the Golgi apparatus, from where it is trafficked to the lysosomes. In this study, we tested glucocerebrosidase protein levels, N-glycans processing and intracellular localization in skin fibroblasts derived from patients with GD. Our results strongly suggest that mutant glucocerebrosidase variants present variable levels of ER retention and undergo ER-associated degradation in the proteasomes. The degree of ER retention and proteasomal degradation is one of the factors that determine GD severity.
UR - http://www.scopus.com/inward/record.url?scp=26444609722&partnerID=8YFLogxK
U2 - 10.1093/hmg/ddi240
DO - 10.1093/hmg/ddi240
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:26444609722
SN - 0964-6906
VL - 14
SP - 2387
EP - 2398
JO - Human Molecular Genetics
JF - Human Molecular Genetics
IS - 16
ER -